Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[Buddhahead]

International Alzheimer's prevention study expands in 13WMAZ article, June 16, 2015

Excerpts:
"A five-year, international study into the genetic roots of the country's sixth-leading killer is expanding. The TOMMORROW study, which is going on in about 50 locations in North America, Europe and Australia, tests a drug — one used to control diabetes — to see whether it could prevent, or at least delay, the onset of Alzheimer's disease"

""It's about delaying the onset of Alzheimer's rather than treating the symptoms" after a diagnosis, he said."

"Participants must be ages 65-83, have no signs of Alzheimer's and carry a set of genetic mutations that are believed to put them at risk for Alzheimer's — something that a blood test at Quest will determine."

"Participants are tested for mutations in the apolipoprotein E gene, or APOE-e, which is associated with an increased number of clumps of proteins known as amyloid and tau. These protein clumps, in turn, have been linked to to Alzheimer's. Researchers also are interested in the gene known as TOMM40, which is believed to interact with APOE-e.

Participants who carry that gene combination will be given either the experimental drug compound pioglitazone or a placebo. Pioglitazone, also known as Actos, is commonly prescribed to help control blood sugar in Type 2 diabetes.

For years, scientists have linked high blood sugar with a greater risk of dementia. Controlling blood sugar may slow a toxic buildup of those proteins."

Article at:
http://www.13wmaz.com/story/news/health/2015/06/15/international-alzheimers-prevention-study-expands/71264946/